Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by LEVINE, M. M.
Right arrow Articles by LIM, Y.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LEVINE, M. M.
Right arrow Articles by LIM, Y.-L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology Vol. 114, No. 3: 348-354
Copyright © 1981 by The Johns Hopkins University School of Hygiene and Public Health


research-article

DURATION OF SERUM ANTITOXIN RESPONSE FOLLOWING VIBRIO CHOLERAE INFECTION IN NORTH AMERICANS: RELEVANCE FOR SEROEPIDEMIOLOGY1

MYRON M. LEVINE, CHARLES R. YOUNG, TIMOTHY P. HUGHES, SYLVIA O'DONNELL, ROBERT E. BLACK, MARY LOU CLEMENTS, ROY ROBINS-BROWNE and YU-LEONG LIM

Reprint requests to Dr. Levine. From the Center for Vaccine Development, U. of Maryland School of Medicine, 29 S. Greene St., Baltimore, MD 21201

Because of repeated infections with bacterial enteropathogens elaborating antigenically related enterotoxins, persons living in less-developed areas even where cholera is not endemic have high prevalence and levels of cholera antitoxin. Thus, in less-developed areas, antitoxin is not helpful for the seroepidemiology of cholera. In contrast, since diarrheal infections due to pathogens elaborating cholera-like enterotoxins are rare in industrialized countries, this study reviewed the magnitude and duration of the serum antitoxin response to cholera infections in North Americans to develop guidelines for use of antitoxin as a seroepidemiologic tool to investigate endemic cholera in the United States. Sera of 31 North American volunteers who ingested Vibrio cholerae in the course of vaccine development studies were examined for immunoglobulin G (IgG) antitoxin by microtiter enzyme-linked immunosorbent assay (ELISA). All 31 had significant rises in antitoxin one month after challenge and provided one or more additional specimens 4–25 months post-inoculation. Seven persons had subclinical infection; the remaining 24 experienced diarrhea. Pre-challenge, 7 of 31 volunteers had low levels of antitoxin, i.e., the net optical density (O.D.) of these sera was greater than the mean net O.D. + 3 standard deviations (SD) of a negative control serum pool known to lack antitoxin by two neutralization assays. The mean antitoxin level at one month post-challenge in the 24 clinically ill persons (net O.D. 1.10) was significantly higher than the mean of the individuals with sub clinical infections (mean net O.D. 0.83) (p < 0.03); the mean net O.D. of the former group remained elevated for at least 25 months. It was decided arbitrarily that a serum IgG ELISA net O.D. should equal or surpass 4 times the net O.D. of the negative control (positive/negative(P/N) ratio≥4) to be considered indicative of past clinical cholera infection. Using this stringent criterion, such net O.D. levels were found in no one pie-challenge, in 30 of 31 at one month post-challenge (one subclinical case did not reach this level), and in 20/24 persons tested 4–25 months after clinical cholera infection. The microtiter ELISA test for serum IgG cholera antitoxin represents an important tool for seroepidemiologic investigation of cholera in the United States and other industrialized countries.

antitoxins; cholera; diarrhea; epidemiologic methods; serodiagnosis; serology; Vibrio cholerae


1From the Center for Vaccine Development, U. of Maryland School of Medicine, 29 S. Greene St., Baltimore, MD 21201.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Infect. Immun.Home page
M. B. Cohen, R. A. Giannella, J. Bean, D. N. Taylor, S. Parker, A. Hoeper, S. Wowk, J. Hawkins, S. K. Kochi, G. Schiff, et al.
Randomized, Controlled Human Challenge Study of the Safety, Immunogenicity, and Protective Efficacy of a Single Dose of Peru-15, a Live Attenuated Oral Cholera Vaccine
Infect. Immun., April 1, 2002; 70(4): 1965 - 1970.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
C. O. Tacket, M. B. Cohen, S. S. Wasserman, G. Losonsky, S. Livio, K. Kotloff, R. Edelman, J. B. Kaper, S. J. Cryz, R. A. Giannella, et al.
Randomized, Double-Blind, Placebo-Controlled, Multicentered Trial of the Efficacy of a Single Dose of Live Oral Cholera Vaccine CVD 103-HgR in Preventing Cholera following Challenge with Vibrio cholerae O1 El Tor Inaba Three Months after Vaccination
Infect. Immun., December 1, 1999; 67(12): 6341 - 6345.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
P. W. Lowry, A. T. Pavia, L. M. McFarland, B. H. Peltier, T. J. Barrett, H. B. Bradford, J. M. Quan, J. Lynch, J. B. Mathison, R. A. Gunn, et al.
Cholera in Louisiana: Widening Spectrum of Seafood Vehicles
Arch Intern Med, September 1, 1989; 149(9): 2079 - 2084.
[Abstract] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.